Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eric Katz

Urology Hartford, CT Medical Doctor

NPI 1598147282 CMS profile 9048415

85 Seymour St Ste 416, Hartford, CT 06106

Open in the dashboard

General payments

$14,060

32 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Katz of Hartford, CT is reported in the CMS Open Payments database as having received $14,060 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $200 4
2024 General $230 1
2023 General $349 6
2022 General $13,149 20
2021 General $132 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Katz
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Eric Katz were reported at $200. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Eric Katz Urology median Middle half National median
2019 $0 $480 $147–$1,201 $163
2020 $0 $246 $87–$645 $114
2021 $132 $358 $111–$1,000 $132
2022 $13,149 $476 $143–$1,263 $149
2023 $349 $560 $168–$1,461 $160
2024 $230 $563 $170–$1,464 $164
2025 $200 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Ethicon Endo-Surgery Inc. $10,337 3 payments
  2. Ethicon Inc. $2,482 13 payments
  3. Boston Scientific Corporation $508 5 payments
  4. Becton, Dickinson and Company $230 1 payment
  5. Calyxo, Inc. $165 2 payments
  6. Photocure Inc $132 1 payment
  7. Intuitive Surgical, Inc. $95 1 payment
  8. Electromed, Inc. $32 2 payments
  9. Coloplast Corp $32 2 payments
  10. Dentsply Ih AB $31 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $10,350 2 payments
  2. Travel and Lodging $2,425 9 payments
  3. Food and Beverage $1,285 21 payments
Products named General payments · program years 2021–2025
  1. Monarch Platform $12,819 16 payments
  2. General - Kidney Stone Disease $150 1 payment
  3. CVAC ASPIRATION SYSTEM $137 1 payment
  4. General - Erectile Dysfunction $137 1 payment
  5. Cysview $132 1 payment
  6. Da Vinci Surgical System $95 1 payment
  7. SMARTVEST $32 2 payments
  8. LoFric $31 1 payment
  9. CVAC $28 1 payment
  10. Luja Coude $16 1 payment
  11. Other $32 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,179

Median for Urology: 1,053

Drug cost

$115,218

Median for Urology: $101,464

Branded share of claims

39.2%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 126 $80,959
Gemtesa Vibegron Brand 26 $21,680
Tamsulosin Hcl Generic 402 $4,901
Finasteride Generic 224 $2,225
Oxybutynin Chloride Er Oxybutynin Chloride Brand 87 $2,139
Alfuzosin Hcl Er Alfuzosin Hcl Brand 91 $1,518
Cefpodoxime Proxetil Generic 16 $684
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 86 $355
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 20 $232
Ciprofloxacin Hcl Generic 27 $178

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$92,091

Medicare's payments for the services billed

Medicare patients

315

Average age 75

Services billed

1,308

44 women, 271 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Ischemic heart disease 38%
Chronic kidney disease 37%
Diabetes 30%
Cancer 26%
Depression 26%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record